Download Product Monograph

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Prescription costs wikipedia , lookup

Neuropharmacology wikipedia , lookup

Biosimilar wikipedia , lookup

Clinical trial wikipedia , lookup

Hormesis wikipedia , lookup

Adherence (medicine) wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Warfarin wikipedia , lookup

Bad Pharma wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Discovery and development of direct thrombin inhibitors wikipedia , lookup

Theralizumab wikipedia , lookup

Dydrogesterone wikipedia , lookup

Bilastine wikipedia , lookup

Transcript

Lesions or conditions at increased risk of clinically significant bleeding, e.g., recent
cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent
bleeding, patients with spontaneous or acquired impairment of hemostasis

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see
ACTION AND CLINICAL PHARMACOLOGY, Hepatic Impairment)

Concomitant treatment with any other anticoagulant, including
o unfractionated heparin (UFH), except at doses used to maintain a patent central
venous or arterial catheter,
o low molecular weight heparins (LMWH), such as enoxaparin and dalteparin,
o heparin derivatives, such as fondaparinux, and
o oral anticoagulants, such as warfarin, dabigatran, apixaban, rivaroxaban except
under circumstances of switching therapy to or from LIXIANA.

Pregnancy (See WARNING AND PRECAUTIONS-Special Populations, Pregnant
Women)

Nursing Women (See WARNING AND PRECAUTIONS-Special Populations, Pregnant
Women)

Hypersensitivity to edoxaban or to any ingredients of the formulation. For a complete
listing of ingredients see DOSAGE FORMS, COMPOSITION AND PACKAGING.
WARNINGS AND PRECAUTIONS
PREMATURE DISCONTINUATION OF ANY ORAL ANTICOAGULANT,
INCLUDING LIXIANA, INCREASES THE RISK OF THROMBOTIC EVENTS.
To reduce this risk, consider coverage with another anticoagulant if LIXIANA is discontinued
for a reason other than pathological bleeding or completion of a course of therapy (see DOSAGE
AND ADMINISTRATION).
The following Warnings and Precautions are listed in alphabetical order.
Bleeding
LIXIANA increases the risk of bleeding and can cause serious, potentially fatal bleeding.
Promptly evaluate any signs or symptoms of blood loss. Discontinue LIXIANA in patients with
clinically significant active bleeding. LIXIANA, like other anticoagulants, must be used with
caution in patients with any increased risk of bleeding. Patients at high risk of bleeding should
not be prescribed LIXIANA (see CONTRAINDICATIONS).
Should severe bleeding occur, treatment with LIXIANA must be discontinued and the
source of bleeding investigated promptly.
LIXIANA® (edoxaban) Product Monograph
Page 4 of 49